Member Info for Henners007

Out now on Sky News - "Coronavirus: Man dies after ingesting chloroquine in attempt to ward off COVID-19
The man's wife said they had watched Donald Trump speaking about the potential benefits of chloroquine.

A man in Arizona has died after ingesting chloroquine phosphate - believing it would protect him from contracting coronavirus.

The man's wife also ingested the substance and is receiving critical care, NBC News reported."

It was great to see and listen to a CEO who truly understands his business and can speak with such authority and confidence about his own professional subject matter - which just so happens to be very topical today.

Wow! What a "straight from the page" interview. If anyone has any doubts or concerns about what we are talking about here. Please make the time and listen to the whole interview. Staggering.

Synairgen was priced at >65p in June 2014. Since when they have improved their product and are in a royalty agreement with Pharmaxis. They have no debt. All the directors are shareholders.

Todays share price represents fair value WITHOUT any CoVid19 related premium.

Apologies for the length of this post. This was a Synairgen RNS from the middle of last year. Please note they were working in Phase II trials to cure Coronavirus related infections before CoVid19 had even appeared. They have specifically been working on this for years.

"An analysis of all the patients dosed to date, as a single group regardless of treatment (the
study will not be unblinded until the end of the trial), shows that cold and flu infections are
having a considerable impact on symptoms in COPD patients, as assessed using the validated
Breathlessness, Cough and Sputum Score (BCSS)3
. A mean decrease in BCSS score > 1
represents substantial symptomatic improvement4
. As we are seeing an increase in mean
BCSS score >2, we have the potential to demonstrate a significant treatment effect. These
changes contrast with the most recent asthma trial, where colds had less impact on patients.
The Company is also pleased to report that the rapid point-of-care test, being used to confirm
that a patient has a viral infection, is ensuring that only the correct patients are being enrolled.
The test ensures that only those patients for whom IFN-beta therapy may be effective are
being dosed, thereby increasing the chance of the drug showing a beneficial effect. To date,
approximately 35% of patients presenting with symptoms have tested positive for a viral
infection. Viruses detected include rhinovirus, influenza, RSV, parainfluenza and coronavirus
infections.

Richard Marsden, CEO of Synairgen, said: “Aided by the rapid point-of-care test, the trial is
successfully capturing marked changes in COPD symptoms in patients with confirmed
common cold and influenza virus infections. We have previously shown that inhaled IFN-beta
boosts the lungs’ antiviral defences in COPD patients and the magnitude of the symptom
changes being observed so far in the current trial puts us in a good position to determine the
potential benefit of inhaled IFN-beta in this patient population"

Alamo. Please read my post earlier today. Even without the current CoVid 19 chit chat on this site, the Synairgen share price is probably sitting NOW at fair value. It is on the cusp of a licensing agreement negotiated with Pharmaxis whereby it waill receive 17% of royalties. This will still happen. The share price had been held back until the Woodford stock sale had been removed from the market place . This has now happened. There is more to come. What price to save the planet from this invisible killer?

Massive Ray - please do some research on this stock. I have been involved since 2011. This company was seriously undervalued without CoVid19. Look at the Pharmaxis website to gain an insight into intrinsic value that has yet to be released.

This latest news released this week may well be some very fat icing on the cake, but their product has already been tried and tested successfully on COPD patients with a similar style condition. The shares reached just shy of 70p in June 2014 without the current froth and chit chat (I was lucky enough to sell out at 66.50p). I genuinely do agree with others that there is no upper calculable limit to the share price based on a successful outcome to the trials which commence next week. Not lecturing (and most definitely not a ramper) just trying to put across balanced viewpoint.

Looks like a UK company may well be at the forefront of finding a vaccine. We are good at that kind of thing!!! Synairgen - ticker SNG. Off topic, apologies.

Agree wholeheartedly with views on AMC taking faaaaar longer than anticipated but all LTH seem to be keeping the faith.

and no AMC trades showing post 10.30 . Why?

Nipped in this morning and bought some at 37.6588p. Quite content.

Anton. Amur minerals has no debt or debt holders.

....and the share price is rising on no (publicly available!!) news whatsoever.

When you consider the wider market malaise since January, down anywhere between 20% and much more depending where you are invested, Synairgen is a beacon of light up >250% since the low of 6p at the beginning of the year. Steady and determined positive price action here.

It is fascinating how many late recorded trades and/or negotiated trades there are in SNG, which "confuse" the buys from sells. The late recorded trades are usually described as "large in scale", and yet in value they are often only £10k. As others have said, it would appear stock is held very tightly with orders being filled, sometimes over several days. Agree with Flappingchicken (great moniker) any positive news breaking here will see the sp head north in double quick time.

Flappingchicken - Presumably you were referring to Page 6 which specifically mentions CoronaVirus four times. Good find. Clearly Synairgen have been aware of and working on remedies linked to Corona Virus (among others) for sometime now. This is their area of expertise. Interesting times.

This chap seems to be very well aligned and connected Patiencepoor.

Ljupco Naumovski, Non-Executive Director

Mr. Naumovski has more than three decades of experience working in Russia, most recently as Vice President and General Director of the Moscow office for Kinross Gold Corporation, the largest Canadian investor in Russia. He also developed the business of Visa International, serving as Senior Vice President and General Manager Visa International Service Organisation (VISA), CEMEA region. Additionally, he served as Senior Banker and Head of Mission for the Russian Team of the European Bank of Reconstruction and Development in Moscow and as Commercial Secretary for the Canadian Embassy in Moscow and later Deputy Director for USSR and Eastern Europe for the Canadian Department of External Affairs and International Trade.

AMC have told all their shareholders and the media that the DFS will be December 2020. This date and timeline is critical. Given everything else that is happening in the world at the moment I am surprised any of us are over interested in a small non producing miner in the far eastern wastelands of Russia. We only have another 9/10 months to wait. Exciting.

The tea leaves are working heavily against us now (and they were biased against us before). CoVid19, Russia standing up against the Saudi's over oil price and production, China/Korea slump in economic activity, reduced demand for commodity's, no 2018 AMC field update. I think we will all have to hunker down for 6 months (or more!!) . Looks like we will be under 1p in short term.

It was well sign posted at the time that Lance Baller had an interest in the Hemp Farm. The conflict of interest was declared.

On the upside, at least the exercise price announced today is 25% higher than the November 2019 cash raise.